Auxilium has said that it plans to reallocate resources to its lead development project, AA4500, indicated for the treatment of Dupuytren's Contracture, a thickening of skin on the palm which causes fingers to curl.
Auxilium expects to begin a second phase III pivotal trial of AA4500 by the end of 2006. Auxilium also recently announced the acquisition of a manufacturing plant for AA4500.
Despite the termination of TestoFilm company believes that the transmucosal film delivery system used in the treatment is viable and intends to develop opportunities in hormone replacement, urologic disease and pain.
“The reallocation of resources will not affect our 2006 guidance with respect to R&D spending or net loss,” said Armando Anido, CEO and president.